CX 802
Alternative Names: CX-802Latest Information Update: 10 Oct 2022
At a glance
- Originator Cartexell
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Haematological malignancies
Most Recent Events
- 21 Sep 2022 Early research in Haematological malignancies in South Korea (Parenteral) (Cartexell pipeline, September 2022)